BACKGROUND: Predicting outcomes for patients with acute myeloid leukemia (AML) on the basis of pretreatment predictors has been the cornerstone of management. Posttreatment prognostic factors are increasingly being evaluated. METHODS: Among 280 younger patients who were treated with intermediate-dose cytarabine (total ≥ 5 g/m2 ) and idarubicin-based induction chemotherapy and achieved remission, 186 were assessed for minimal residual disease (MRD) with an 8-color multiparameter flow cytometry panel performed on bone marrow specimens with a sensitivity of 0.1% or higher. RESULTS: One hundred sixty-six patients had samples available 1 to 2 months after induction at the time of complete remission (CR), and 79% became negative for MRD, with an MRD-negative status associated with an improvement in relapse-free survival (RFS; P = .0002) and overall survival (OS; P = .0002). One hundred sixteen were evaluated for their MRD status during consolidation, and 86% were negative, with an MRD-negative status associated with a significant improvement in RFS (P < .0001) and OS (P < .0001). Sixty-nine patients were evaluated for their MRD status after completion of all therapy, and 84% were negative, with an MRD-negative status associated with an improvement in RFS (P < .0001) and OS (P < .0001). In a multivariate analysis including age, cytogenetics, response (CR vs CR with incomplete platelet recovery/incomplete blood count recovery), and MRD, achieving an MRD-negative status was the most important independent predictor of RFS and OS at response (P = .008 and P = .0008, respectively), during consolidation (P < .0001 for both), and at the completion of therapy (P < .0001 and P = .002, respectively). CONCLUSIONS: Achieving an MRD-negative status according to multiparameter flow cytometry is associated with a highly significant improvement in the outcomes of younger patients with AML receiving cytosine arabinoside plus idarubicin-based induction and consolidation regimens. Cancer 2017;123:426-435.
BACKGROUND: Predicting outcomes for patients with acute myeloid leukemia (AML) on the basis of pretreatment predictors has been the cornerstone of management. Posttreatment prognostic factors are increasingly being evaluated. METHODS: Among 280 younger patients who were treated with intermediate-dose cytarabine (total ≥ 5 g/m2 ) and idarubicin-based induction chemotherapy and achieved remission, 186 were assessed for minimal residual disease (MRD) with an 8-color multiparameter flow cytometry panel performed on bone marrow specimens with a sensitivity of 0.1% or higher. RESULTS: One hundred sixty-six patients had samples available 1 to 2 months after induction at the time of complete remission (CR), and 79% became negative for MRD, with an MRD-negative status associated with an improvement in relapse-free survival (RFS; P = .0002) and overall survival (OS; P = .0002). One hundred sixteen were evaluated for their MRD status during consolidation, and 86% were negative, with an MRD-negative status associated with a significant improvement in RFS (P < .0001) and OS (P < .0001). Sixty-nine patients were evaluated for their MRD status after completion of all therapy, and 84% were negative, with an MRD-negative status associated with an improvement in RFS (P < .0001) and OS (P < .0001). In a multivariate analysis including age, cytogenetics, response (CR vs CR with incomplete platelet recovery/incomplete blood count recovery), and MRD, achieving an MRD-negative status was the most important independent predictor of RFS and OS at response (P = .008 and P = .0008, respectively), during consolidation (P < .0001 for both), and at the completion of therapy (P < .0001 and P = .002, respectively). CONCLUSIONS: Achieving an MRD-negative status according to multiparameter flow cytometry is associated with a highly significant improvement in the outcomes of younger patients with AML receiving cytosine arabinoside plus idarubicin-based induction and consolidation regimens. Cancer 2017;123:426-435.
Authors: Jeffrey E Rubnitz; Hiroto Inaba; Gary Dahl; Raul C Ribeiro; W Paul Bowman; Jeffrey Taub; Stanley Pounds; Bassem I Razzouk; Norman J Lacayo; Xueyuan Cao; Soheil Meshinchi; Barbara Degar; Gladstone Airewele; Susana C Raimondi; Mihaela Onciu; Elaine Coustan-Smith; James R Downing; Wing Leung; Ching-Hon Pui; Dario Campana Journal: Lancet Oncol Date: 2010-05-05 Impact factor: 41.316
Authors: E H Estey; P F Thall; S Pierce; J Cortes; M Beran; H Kantarjian; M J Keating; M Andreeff; E Freireich Journal: Blood Date: 1999-04-15 Impact factor: 22.113
Authors: Ching-Hon Pui; Deqing Pei; Elaine Coustan-Smith; Sima Jeha; Cheng Cheng; W Paul Bowman; John T Sandlund; Raul C Ribeiro; Jeffrey E Rubnitz; Hiroto Inaba; Deepa Bhojwani; Tanja A Gruber; Wing H Leung; James R Downing; William E Evans; Mary V Relling; Dario Campana Journal: Lancet Oncol Date: 2015-03-20 Impact factor: 41.316
Authors: J B Nachman; H N Sather; M G Sensel; M E Trigg; J M Cherlow; J N Lukens; L Wolff; F M Uckun; P S Gaynon Journal: N Engl J Med Date: 1998-06-04 Impact factor: 91.245
Authors: Adam Ivey; Robert K Hills; Michael A Simpson; Jelena V Jovanovic; Amanda Gilkes; Angela Grech; Yashma Patel; Neesa Bhudia; Hassan Farah; Joanne Mason; Kerry Wall; Susanna Akiki; Michael Griffiths; Ellen Solomon; Frank McCaughan; David C Linch; Rosemary E Gale; Paresh Vyas; Sylvie D Freeman; Nigel Russell; Alan K Burnett; David Grimwade Journal: N Engl J Med Date: 2016-01-20 Impact factor: 91.245
Authors: Nicholas J Short; Hind Rafei; Naval Daver; Hyunsoo Hwang; Jing Ning; Jeffrey L Jorgensen; Tapan M Kadia; Courtney D DiNardo; Sa A Wang; Elias Jabbour; Uday Popat; Betul Oran; Jorge Cortes; Marina Konopleva; Musa Yilmaz; Ghayas C Issa; Hagop Kantarjian; Farhad Ravandi Journal: Blood Adv Date: 2020-12-22
Authors: P Boddu; J Jorgensen; H Kantarjian; G Borthakur; T Kadia; N Daver; Y Alvarado; N Pemmaraju; P Bose; K Naqvi; M Yilmaz; S Pierce; M Brandt; C D DiNardo; E J Jabbour; M Konopleva; G Garcia-Manero; J Cortes; F Ravandi Journal: Leukemia Date: 2017-09-18 Impact factor: 11.528
Authors: Richard Dillon; Robert Hills; Sylvie Freeman; Nicola Potter; Jelena Jovanovic; Adam Ivey; Anju Shankar Kanda; Manohursingh Runglall; Nicola Foot; Mikel Valganon; Asim Khwaja; Jamie Cavenagh; Matthew Smith; Hans Beier Ommen; Ulrik Malthe Overgaard; Mike Dennis; Steven Knapper; Harpreet Kaur; David Taussig; Priyanka Mehta; Kavita Raj; Igor Novitzky-Basso; Emmanouil Nikolousis; Robert Danby; Pramila Krishnamurthy; Kate Hill; Damian Finnegan; Samah Alimam; Erin Hurst; Peter Johnson; Anjum Khan; Rahuman Salim; Charles Craddock; Ruth Spearing; Amanda Gilkes; Rosemary Gale; Alan Burnett; Nigel H Russell; David Grimwade Journal: Blood Date: 2020-02-27 Impact factor: 22.113
Authors: Sylvie D Freeman; Robert K Hills; Paul Virgo; Naeem Khan; Steve Couzens; Richard Dillon; Amanda Gilkes; Laura Upton; Ove Juul Nielsen; James D Cavenagh; Gail Jones; Asim Khwaja; Paul Cahalin; Ian Thomas; David Grimwade; Alan K Burnett; Nigel H Russell Journal: J Clin Oncol Date: 2018-03-30 Impact factor: 44.544